Pfizer's booth at the China International Import Expo in Shanghai, Nov. 7, 2024. [Photo by Wang Yiming/China.org.cn]

Pfizer showcased new treatments for atopic dermatitis, the leading type of eczema, at the 7th China International Import Expo (CIIE), targeting the country's growing demand for skin disease solutions.

The company featured two therapies: Cibinqo (abrocitinib tablets) and Staquis (crisaborole ointment), offering treatment options for various severity levels of the condition.

"This year marks Pfizer's sixth appearance at the CIIE, our 175th anniversary globally, and 35 years of operations in China," said Liu Jing, general manager of Pfizer China's Inflammation and Immunology Franchise.

Liu noted that inflammation and immunology remain a key strategic priority for Pfizer. "We have spent the past three decades pioneering JAK inhibitors to treat inflammatory immune diseases, benefiting over 70 million AD patients in China."

"We will continue to drive scientific exploration, actively promote real-world studies, and constantly leverage evidence-based medicine to advance standardized atopic dermatitis care in China, thus helping realize the 'Healthy China 2030' initiative," Liu added.

Liu Jing, general manager of Pfizer China's Inflammation and Immunology Franchise, speaks at the 7th China International Import Expo in Shanghai, Nov. 7, 2024. [Photo courtesy of Pfizer]

Pfizer has launched several research initiatives in China, including an Abrocitinib Chinese Registry on atopic dermatitis, headed by Yao Zhirong, dermatology director at Xinhua Hospital, which is affiliated with Shanghai Jiao Tong University School of Medicine.

According to Yao, the study will encompass more than 1,000 patients across over 40 institutions nationwide.

The research aims to develop standardized diagnosis and treatment protocols for atopic dermatitis, both domestically and internationally, while establishing scientific medication guidelines under the treat-to-target framework.

"This study brings the 'voice of Chinese science' to the world," he said.

The pharmaceutical company is collaborating with local media and healthcare organizations to boost public awareness and patient education about atopic dermatitis. Its initiatives include the "China Skin Health Action Plan," focused on improving disease understanding and management through medical education.